Vitrakvi (larotrectinib) — Medica
pediatric diffuse high-grade gliomas
Initial criteria
- Patient is age ≤ 21 years
- The tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion
- Patient meets ONE of the following: the medication is used as adjuvant therapy OR the medication is used for recurrent or progressive disease
Approval duration
1 year